

FOR IMMEDIATE RELEASE
Sept. 28, 2021

For more information: Dan Shuman
daniel@shuman@lifenethealth.org
757-609-4330 office
757-374-5316 cell

LifeNet Health's ViviGen® MIS optimizes leading cellular allograft for minimally invasive procedures

New solution for surgeons brings unrivaled precision, efficiency and reliability to bone grafting in MIS spine and orthopedic surgery

Boston, Mass. (Sept. 28, 2021) — [LifeNet Health](#), the world leader in allograft biologics, has optimized its industry-leading cellular bone matrix for minimally invasive surgery with the launch of ViviGen® MIS Delivery System, a major improvement in precision, efficiency and reliability over traditional bone-graft delivery.

ViviGen MIS is the latest addition to the [ViviGen family of cellular allografts](#), the first and only cellular biologics focused on recovering and protecting lineage-committed bone cells. The new delivery system offers a simple delivery method that is up to three-times faster than existing solutions like bone funnels.

“ViviGen MIS brings graft delivery for minimally invasive procedures into the 21st Century,” said Rony Thomas, President and CEO of LifeNet Health. “It is a quantum leap forward that combines the clinical advantages of ViviGen with a fast, consistent delivery experience that eliminates one of the lingering challenges in MIS procedures. We are proud to bring this exciting solution to clinicians to support their patients’ healing.”

The ViviGen MIS system includes two single-use components: a pre-filled cannula containing the graft material and an easy-to-use delivery device. The convenience of a pre-filled cannula removes the difficulty and inconsistency associated with other bone graft-delivery options. The system facilitates rapid thawing of the graft, and it takes mere seconds to attach a cannula to the delivery device. ViviGen MIS is indicated for spine and orthopedic procedures requiring a bone graft.

Since its launch in 2014, ViviGen has grown into the world’s leading cellular allograft, having been implanted in nearly 200,000 patients. It is comprised of cryopreserved, cortical cancellous bone matrix containing viable bone cells and demineralized bone to provide the three critical elements for bone healing — osteoconductivity, osteoinductivity and osteogenecity — that make ViviGen a viable alternative to autograft.

A growing body of published data illustrates the clinical advantages of ViviGen. Studies have shown that it supports fusion rates as high as 98 percent even in [complex, multi-level fusions](#) while also being associated with [significantly lower hospital charges](#) than other grafting solutions. Learn more at www.lifenethealth.org/vivigen.

About LifeNet Health

LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.